Live Feeds
● TRACKER Updated 17d ago · 8 sources tracked

As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground

The FDA has approved daraxonrasib, marketed as RASONQUE, a breakthrough pill developed by RevMed to treat pancreatic cancer. The drug carries a monthly list price of $39,800. While described as a transformative treatment for a deadly disease, the launch faces scrutiny regarding its practical implementation on the ground. The medication is already being used by some patients, including a Philadelphia police officer who stated the treatment gives him hope.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The FDA approved the drug daraxonrasib for the treatment of pancreatic cancer.
  • ✓ RevMed developed the breakthrough pill.
  • ✓ The drug is marketed under the name RASONQUE.
🛡️ Source Corroboration: 8 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The FDA approved RevMed's daraxonrasib (RASONQUE) for pancreatic cancer treatment.

Live updates

  1. FDA Approves RevMed Pancreatic Cancer Pill RASONQUE

    The FDA has approved daraxonrasib, marketed as RASONQUE, a breakthrough pill developed by RevMed to treat pancreatic cancer. The drug carries a monthly list price of $39,800. While described as a transformative treatment for a deadly disease, the launch faces scrutiny regarding its practical implementation on the ground. The medication is already being used by some patients, including a Philadelphia police officer who stated the treatment gives him hope.

    Why it matters

    Pancreatic cancer is characterized as a deadly disease with limited treatment options. This approval marks a new era for care by introducing a targeted pill. RevMed has remained an independent company during the development of this therapy.

    What is confirmed

    • The FDA approved the drug daraxonrasib for the treatment of pancreatic cancer.
    • RevMed developed the breakthrough pill.
    • The drug is marketed under the name RASONQUE.

    Still unconfirmed

    • The monthly list price for the drug is $39,800.
    • Questions linger on the ground as RevMed prepares for the launch.

    What to watch next

    • Insurance coverage determinations for the $39,800 monthly cost
    • Clinical outcomes data from wider patient populations
    • Development of similar medicines in the current competitive race
    Sources used for this update (11)
    1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
    2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
    3. Bloomberg — FDA Approves RevMed’s Breakthrough Pill for Pancreatic Cancer
    4. Bloomberg — A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment
    5. BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
    6. Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
    7. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
    8. Fierce Pharma — As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
    9. WSJ — Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
    10. CBS News — Philadelphia police officer takes newly approved drug for pancreatic cancer: "It gives me hope"
    11. Yahoo Finance — New pancreatic cancer drug carries a $39,800 monthly list price: What to know
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community